激素受体阳性HER2阴性转移性乳腺癌一线内分泌治疗或化疗的比较
倾向性评分校正后,两组总生存无显著差异(HR 0.943,95%CI 0.863-1.030,P=0.19),支持在无内脏危象时首选内分泌治疗。
要点
- 对AI敏感的HR+ HER2-转移性乳腺癌,一线化疗与内分泌治疗的总生存相似。
- 倾向性评分校正后HR 0.943(95%CI 0.863-1.030,P=0.19),差异无统计学意义。
- 无内脏危象时,内分泌治疗应作为一线系统治疗首选。
核心结论
- 在AI敏感的转移性luminal乳腺癌患者中,一线化疗或内分泌治疗的总生存相似。
- 无内脏危象时,内分泌治疗应作为转移性乳腺癌一线系统治疗的首选。
研究设计与样本
- 基于法国UNICANCER ESME大型全国观察性数据库(NCT03275311)的回顾性队列研究。
- 要求患者对芳香化酶抑制剂敏感(既往未用AI或末次辅助AI后复发超过1年)。
主要发现
- 2733例(43.6%)接受单纯内分泌治疗,3532例(56.4%)接受一线化疗。
- 化疗组中2073例(58.7%)接受了维持内分泌治疗。
- 单纯内分泌治疗组中位OS为60.78个月(95%CI 57.16-64.09),化疗±维持内分泌治疗组为49.64个月(95%CI 47.31-51.64),P<0.0001。
- 倾向性评分校正后,两组OS差异无统计学意义(HR 0.943,95%CI 0.863-1.030,P=0.19)。
临床怎么用
- 对AI敏感的HR+ HER2-转移性乳腺癌,无内脏危象时应优先选择内分泌治疗作为一线方案。
- 内脏危象患者仍按指南考虑一线化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2-) negative metastatic breast cancer (MBC), international guidelines recommend endocrine therapy as first-line treatment, except in case of 'visceral crisis'. In the latter case, chemotherapy is preferred. Few studies have compared these two strategies. We used the Epidemiological Strategy and Medical Economics (ESME) programme, UNICANCER, a large national observational database (NCT03275311), to address this question. METHODS: All patients who initiated treatment for a newly diagnosed HR+ HER2-negative MBC between January 2008 and December 2014 in any of the 18 French Comprehensive Cancer Centers participating to ESME were selected. Patients should be aromatase inhibitor (AI)-sensitive (no previous AI or relapse occurring more than 1 year after last adjuvant AI). Objectives of the study were evaluation of progression-free and overall survival (OS) according to the type of first-line treatment adjusted on main prognostic factors using a propensity score. RESULTS: Six thousand two hundred sixty-five patients were selected: 2733 (43.6%) received endocrine therapy alone, while 3532 (56.4%) received chemotherapy as first-line therapy. Among the latter, 2073 (58.7%) received maintenance endocrine therapy. Median OS was 60.78 months (95% confidence interval [CI], 57.16-64.09) and 49.64 months (95% CI, 47.31-51.64; p < 0.0001) for patients receiving endocrine therapy alone and chemotherapy ± maintenance endocrine therapy, respectively. However, this difference was not significant after adjusting on the propensity score (hazard ratio: 0.943, 95% CI 0.863-1.030, p = 0.19). CONCLUSION: In this large retrospective cohort of patients with AI-sensitive metastatic luminal BC, OS was similar, whether first-line treatment was chemotherapy or endocrine therapy. In agreement with international guidelines, endocrine therapy should be the first choice for first-line systemic treatment for MBC in the absence of visceral crisis.
引用
- Jacquet E, Lardy-Cléaud A, Pistilli B, et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur J Cancer. 2018. PMID: 29655061. doi:10.1016/j.ejca.2018.03.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。